In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis

Neurology

Volumn 50, Issue 5, 1998, Pages 1294-1300

  Rudick, Richard ^a   Ransohoff, R M ^a   Lee, J C ^a   Peppler, R ^a   Yu, M ^a   Mathisen, P M ^a   Tuohy, V K ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; CYTOKINE; GAMMA INTERFERON; INTERFERON BETA SERINE; INTERLEUKIN 10; INTERLEUKIN 4; PROTEOLIPID PROTEIN; RECOMBINANT BETA INTERFERON;

ADULT; ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MULTIPLE SCLEROSIS; NONHUMAN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0031816173     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.50.5.1294     Document Type: Article

References (21)

1. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.
2. The IFNB Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
3. Jacobs L, Cookfair DL, Rudick RA, et al. A phase III trial of intramuscular recombinant beta interferon as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis 1995;1:118-135.
4. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
5. Yu M, Johnson JM, Tuohy VK. A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: a basis for peptide-specific therapy after onset of clinical disease. J Exp Med 1996;183:1777-1788.
6. Yu M, Nishiyama A, Trapp BD, Tuohy VK. Interferon-beta inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis. J Neuroimmunol 1996;64:91-100.
7. Rudick RA, Ransohoff RM, Peppler R, VanderBrug Medendorp S, Lehmann P, Alam J. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann Neurol 1996;40:618-627.
8. Ransohoff RM, Hamilton TA, Tani M, et al. Astrocyte expression of mRNA encoding cytokines IP-10 and JE/MCP-1 in experimental autoimmune encephalomyelitis. FASEB J 1993; 7:592-600.
9. Moore KW, Vieira P, Fiorentino DF, Trounstine ML, Khan TA, Mosmann TR. Homology of cytokine synthesis inhibitory factor (IL-10) to Epstein-Barr virus gene BCRFI. Science 1997;24:1230-1234.
10. Lee F, Yokota T, Otsuka T, et al. Isolation and characterization of a mouse interleukin cDNA clone that expresses B-cell stimulatory factor 1 activities and T-cell-and mast-cell-stimulating activities. Proc Natl Acad Sci USA 1986;83:2061-2965.
11. Erdreich LS, Lee ET. Use of relative operating characteristic analysis in epidemiology: a method for dealing with subjective judgments. Am J Epidemiol 1981;114:649-662.
12. Rep MHG, Hintzen RQ, Polman CH, van Lier RAW. Recombinant interferon-β blocks proliferation but enhances interleukin-10 secretion by activated human T-cells. J Neuroimmunol 1996;67:111-118.
13. Lu HT, Riley JL, Babcock GT, et al. Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3-gamma. J Exp Med 1995;182: 1517-1525.
14. Leppert D, Waubant E, Burk MR, Oksenbert JR, Hauser SL. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 1997;40:846-852.
15. Stuve O, Dooley NP, Uhm JH, et al. Interferon-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 1997;40:853-863.
16. Calabresi PA, Tranquill LR, Dambrosia JM, et al. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with Interferon β-1b. Ann Neurol 1997;41:669-674.
17. Noronha A, Toscas A, Jensen MA. Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis. J Neuroimmunol 1993;46:145-153.
18. Rudick RA, Cookfair D, Ransohoff R, et al. CSF abnormalities in a phase III trial of Avonex (IFNβ-1a) for relapsing multiple sclerosis. Ann Neurol 1996;40:516.
19. Rudick RA, Carpenter CS, Cookfair DL, Tuohy VK, Ransohoff RM. In vitro and in vivo inhibition of mitogen-driven T-cell activation by recombinant interferon beta. Neurology 1993;43: 2080-2087.
20. Weinstock-Guttman B, Ransohoff RM, Rudick RA, Kinkel RP. Recombinant interferon beta 1b (Betaseron) induces expression of early T-cell activation markers in multiple sclerosis patients. Neurology 1995;45:196.
21. Glabinski AR, Balasingam V, Tani M, et al. Chemokine monocyte chemoattractant protein-1 is expressed by astrocytes after mechanical injury to the brain. J Immunol 1996;156:4363-4368.